Feiwei Heji Enhances Antitumor Immunity by MLL4‐Dependent Regulation of Pyroptosis in Lung Cancer Authors: Nan Cheng, Ruoyu Jiang, Wei Li, Wenjie Huang, Qiao Peng, Tong Zhao, Chufeng Zhang Published: 2026 ABSTRACT ABSTRACTFeiwei Heji (FWHJ) is a traditional Chinese medicine formula used for lung cancer with Qi‐Yin deficiency. This study investigated the antitumor effect of FWHJ on lung cancer and explored the underlying mechanisms. The major chemical components of FWHJ were identified by HPLC. Lewis lung carcinoma (LLC) tumor‐bearing mice received oral FWHJ at different doses. Tumor histopathology was assessed by H&E and TUNEL staining. Expression of MLL4, pyroptosis‐related proteins (NLRP3, caspase‐1, and GSDMD), and inflammatory cytokines (IL‐1β and IFN‐β) was detected by Western blot, immunohistochemistry, and ELISA. Tumor‐infiltrating immune cells were evaluated by flow cytometry. An MLL4 overexpression model was established to validate the role of MLL4 in the antitumor effects of FWHJ. HPLC analysis showed that FWHJ primarily contains naringin, chlorogenic acid, amygdalin, and harpagoside. Oral FWHJ significantly inhibited tumor growth, upregulated NLRP3, caspase‐1, and GSDMD, as well as their cleaved forms, and increased the release of IL‐1β and IFN‐β, indicating the activation of pyroptosis. FWJH also enhanced antitumor immunity, characterized by an increased CD8+/CD4+ T cells ratio and elevated proportion of CD28+ and IFN‐γ+ CD8+ T cells in the tumor microenvironment. Mechanistically, FWHJ significantly downregulated MLL4 expression, and MLL4 overexpression largely attenuated its antitumor and immune‐enhancing effects. These findings suggest that FWHJ suppresses lung cancer progression by downregulating MLL4, activating pyroptosis, and promoting immune cell infiltration, highlighting that MLL4 may serve as a key regulator mediating the antitumor effects of FWHJ.Keywords: Feiwei Heji (FWHJ), immune response, lung cancer, MLL4, pyroptosis Abbreviations cysteine‐aspartic protease‐1 activated caspase‐1 fragment danger‐associated molecular patterns double‐stranded RNA Feiwei Heji gasdermin‐D full‐length gasdermin‐D N‐terminal fragment of gasdermin‐D Lewis lung carcinoma mixed‐lineage leukemia protein‐4 NOD‐like receptor family pyrin domain‐containing‐3 terminal deoxynucleotidyl transferase dUTP nick‐end labeling vesicular stomatitis virus glycoprotein Introduction Lung cancer is one of the most prevalent malignancies worldwide, exhibiting the highest incidence and mortality rates [1]. Despite recent advances in early detection, treatment, and prognosis, therapeutic outcomes for advanced lung cancer remain unsatisfactory, with a low 5‐year survival rate [2]. Currently, clinical treatments mainly include surgical resection, chemoradiotherapy, and targeted therapy; however, these approaches have limitations in efficacy and are often accompanied by adverse effects. Pyroptosis is an inflammatory programmed cell death mediated by gasdermin (GSDM) proteins. It is characterized by the formation of membrane pores and the massive release of inflammatory factors, such as IL‐1β and IL‐18, thereby triggering immune cell recruitment and immune responses [3]. Recent studies have revealed that pyroptosis plays a pivotal role in remodeling the tumor immune microenvironment, thereby enhancing antitumor immune responses and improving the efficacy of immunotherapy [4]. Mixed lineage leukemia 4 (MLL4, also known as KMT2D) is a histone H3K4 methyltransferase involved in chromatin remodeling and gene transcription regulation [5]. MLL4 influences cell differentiation and metabolism and contributes to tumor progression. Recent studies indicate that aberrant expression of MLL4 is closely associated with reduced immune cell infiltration and may suppress antitumor immune responses. Specifically, MLL4 deficiency can trigger pyroptosis and significantly enhance tumor‐infiltrating CD8+ T cells and antitumor immunity [6]. These findings suggest that MLL4 plays a dual role in regulating pyroptosis and tumor immune infiltration. FWHJ is an in‐house traditional Chinese medicine formulation used for the treatment of lung cancer associated with Qi‐Yin deficiency. It contains Astragalus membranaceus, Adenophora stricta, Glehnia littoralis , Trichosanthes kirilowii, Prunus armeniaca , Scrophularia ningpoensis, Belamcanda chinensis , Fritillaria cirrhosa, among other herbs [7]. Previous studies have shown its therapeutic efficacy against lung cancer, and it has been widely used in the management of pulmonary diseases and as adjuvant therapy for lung cancer. However, the molecular mechanisms underlying its antitumor effects remain unclear. In this study, we investigated the effects of FWHJ on subcutaneous tumor growth and immune cell infiltration in a lung cancer murine model and explored the key regulatory role of MLL4 in mediating its antitumor action. Our findings provide a new insight into the mechanism of FWHJ and offer experimental evidence to support its potential application in clinical lung cancer therapy. Materials and Methods Preparation of FWHJ FWHJ was composed of 16 herbal ingredients: 9 g Roast Stemona, 9 g Radix scrophulariae, 9 g semen lepidii, 9 g seaweed, 9 g Chenpi, 4.5 g rhizoma bolbostemmae, 12 g Adenophora stricta, 12 g radix clematidis, 12 g seed of Job's tears, 12 g mulberry bark, 15 g honeysuckle, 15 g Fructus trichosanthis, 3 g Almond, 30 g rhizoma phragmitis, 10 g Burning Loquat Leaves, and 3.25 g red dates. All herbs were obtained from the Pharmacy Department of Shandong Cancer Hospital. The herbs were first soaked in 10 volumes of cold distilled water for 1 h, then boiled and decocted for 40 min. After filtration, the residue was decocted again with eight volumes of distilled water. The combined filtrates were concentrated using a rotary evaporator to yield a crude extract at a final concentration of 1 g of herbal material per milliliter (w/v). The resulting extract was sterilized by sequential filtration through 0.45 μm and 0.22 μm membranes and stored at 4°C until further use. High‐performance liquid chromatography (HPLC) was employed to profile the main chemical constituents of FWHJ. Reference standards including hesperidin, amygdalin, harpagoside, and chlorogenic acid (purity > 98%) were obtained from Shanghai Macklin Biochemical Co. Ltd. For HPLC analysis, the extract was prepared at 1 g/mL (1 mL solution contains 1 g of original herbs). Reagents and Antibodies ELISA kits for IL‐1β and IFN‐β were purchased from Shanghai Zhuocai Biotechnology Co. Ltd. (ZC‐37974 and ZC‐37887). TUNEL apoptosis detection kit (G1502) was provided by Sevier Biotechnology. Anti‐MLL4 antibody (Ab56770, 1:500) and recombinant Anti‐GSDMD antibody (ab219800, 1:1000) were purchased from Abcam. Anti‐GSDMD‐N antibody (DF13758, 1:1000) was obtained from Affinity. Anti‐MLL4 Polyclonal antibody (PA5‐103371, 1:250) was purchased from Invitrogen. Anti‐NLRP3 antibody (15101, 1:500), anti‐caspase‐1 antibody (24232, 1:1000), anti‐cleaved‐caspase‐1 antibody (89332, 1:1000), anti‐GSDMD‐F antibody (39754, 1:1000), anti‐GAPDH antibody (5174, 1:5000), anti‐rabbit IgG (H + L) antibody (14708, 1:5000), and anti‐mouse IgG (H + L) antibody (14709, 1:5000) were all purchased from Cell Signaling Technology. PerCP/Cyanine5.5 anti‐mouse CD45 antibody (E‐AB‐F1136J, 1:50), APC anti‐mouse CD3 antibody (E‐AB‐F1013E, 1:50), FITC anti‐mouse CD8a antibody (E‐AB‐F1104C, 1:50), PE anti‐mouse CD4 antibody (E‐AB‐F1097D, 1:50), APC anti‐mouse CD8a antibody (E‐AB‐F1104E, 1:50), PE anti‐mouse CD28 antibody (E‐AB‐F1026D, 1:50), and PE anti‐mouse IFN‐γ antibody (E‐AB‐F1101D, 1:50) were all purchased from Elabscience. Cell Culture and Animals Cells Lewis lung carcinoma (LLC) cells were obtained from the Shanghai Cell Bank, Chinese Academy of Sciences. Cells were cultured in DMEM medium (HyClone, USA) supplemented with 10% fetal bovine serum (FBS, Biowest, France), 1% penicillin (100 U/mL), and 1% streptomycin (100 U/mL) (Yeasen, China). All cells were maintained in a humidified incubator at 37°C with 5% CO2. Animals Eight‐week‐old SPF male BALB/c mice (weighing 20–22 g) were purchased from Shanghai SLAC Laboratory Animal Co. Ltd. Mice were housed at 22°C ± 2°C with 50%–60% relative humidity under a 12‐h light/dark cycle, with free access to food and water. All animal experiments were conducted in accordance with the Basel Declaration's tenets and the Laboratory Animal‐Guideline for Ethical Review of Animal Welfare (GB/T 35892‐2018) recommended by the Institutional Animal Care and Use Committee of Nanjing University of Chinese Medicine (animal ethics approval number 202401A041). Establishment of Subcutaneous Tumor Model LLC cells in logarithmic growth phase were collected and resuspended in PBS. Each mouse was subcutaneously injected in the right axilla with 100 μL PBS containing 1 × 106 LLC cells to establish the subcutaneous tumor model. About 5–7 days post‐inoculation, when tumor volumes reached approximately 100 mm3, drug administration began. Mice were randomly divided into five groups (n = 6 per group): Model group (Model), low‐dose group (FWHJ‐L, 1.17 g/kg), medium‐dose group (FWHJ‐M, 2.34 g/kg), high‐dose group (FWHJ‐H, 4.68 g/kg), and positive control group (Positive, 5 mg/kg cisplatin) (D807330, Macklin). Drugs were administered daily via oral gavage for 14 days, and the model group received equal volumes of saline. Tumor volume was calculated using the formula: volume = (length × width2)/2. Body weight and tumor volume were measured daily. At the end of the experiment, mice were sacrificed, tumors were excised, and tissues were collected for subsequent experiments. High‐Performance Liquid Chromatography (HPLC) The main chemical components of FWHJ were qualitatively and quantitatively analyzed by HPLC. Briefly, 1 mL of FWHJ concentrated solution was diluted to 10 mL with methanol, sonicated for 30 min, and centrifuged at 3000 rpm for 5 min. The supernatant was filtered through a 0.22 μm microporous membrane and used as the test solution. Reference standards (Chlorogenic acid, Amygdalin, Harpagoside, Naringin; purity ≥ 98%) were purchased from Shanghai Macklin Biochemical Co. Ltd. Quantification was performed using the external standard method. Chromatographic conditions were as follows: column, C18 (250 mm × 4.6 mm, 5 μm); mobile phase, acetonitrile (B)—0.1% aqueous formic acid (A) gradient elution; flow rate, 1.0 mL/min; column temperature, 30°C; detection wavelength, 280 nm; and injection volume, 10 μL. H&E Staining Tumor tissues were immediately fixed in 4% paraformaldehyde for 24–48 h, dehydrated, embedded in paraffin, and sectioned at 5 μm thickness. Sections were deparaffinized in xylene I (20 min) and xylene II (20 min), then hydrated through an ethanol series (100% I, 100% II, 75%) for 5 min each, followed by rinsing in running water for 2 min. Sections were stained with hematoxylin for 3–5 min and rinsed until the color stabilized. Differentiation and subsequent washing were performed, followed by eosin counterstaining for 1–2 min. Sections were dehydrated with 95% and 100% ethanol once each, cleared in xylene twice (5 min each), mounted with neutral resin, air‐dried, and observed under a light microscope for histomorphological assessment. TUNEL Staining TUNEL staining was performed according to the manufacturer's instructions. After deparaffinization and hydration, 100 μL of TUNEL reaction solution was added to each section and incubated at 37°C in the dark for 1 h. Sections were washed with PBS three times (5 min each), followed by DAPI staining for 10 min. Fluorescence microscopy was used to observe the samples, and ImageJ software was used to count TUNEL‐positive cells and total cells. Western Blot Analysis Total protein was extracted from fresh tumor tissues, and protein concentrations were determined using the BCA method. Equal amounts of protein (30–50 μg) were separated by SDS–PAGE and transferred to PVDF membranes. Membranes were blocked in 5% nonfat milk at room temperature for 1 h and incubated with primary antibodies (1:1000) at 4°C overnight. After washing with TBST three times (15 min each), membranes were incubated with secondary antibodies at room temperature for 1 h. Signals were detected using ECL chemiluminescence, and band intensities were quantified with ImageJ software. Relative protein expression was normalized to GAPDH. Immunohistochemistry Paraffin‐embedded tumor tissue sections underwent antigen retrieval, followed by incubation with 3% hydrogen peroxide for 10 min to inactivate endogenous peroxidase. Sections were incubated with primary antibodies (MLL4 and GSDMD) at 4°C overnight, followed by HRP‐conjugated secondary antibodies for 30 min at room temperature. DAB was used for color development; sections were counterstained with hematoxylin, and images were captured with a microscope. Relative protein expression levels were analyzed using ImageJ. Enzyme‐Linked Immunosorbent Assay (ELISA) Tumor tissues were homogenized in cold phosphate‐buffered saline (pH 7.4) and centrifuged at 10,000 rpm, 4°C for 15 min. A total of 100 μL of supernatant was used for ELISA to measure IL‐1β and IFN‐β concentrations according to the manufacturer's instructions. Absorbance at 450 nm was measured, and cytokine concentrations were calculated using standard curves. Flow Cytometry Tumor tissues were mechanically minced and digested to prepare single‐cell suspensions. After red blood cell lysis, the cells were centrifuged and resuspended in flow cytometry buffer. Approximately 1 × 106 cells were incubated with surface marker antibodies (CD4, CD8, and CD28) at 4°C in the dark for 30 min, gently mixed every 5 min. After washing with PBS, the cells were fixed and permeabilized for 30 min at 4°C. For intracellular IFN‐γ detection, permeabilized cells were incubated with anti‐IFN‐γ antibody for 30 min at 4°C in the dark. The cells were washed, resuspended in buffer, and analyzed by flow cytometry using FlowJo software. Construction of MLL4 Overexpression Model The MLL4 overexpression vector (lenti‐OE MLL4) was constructed and verified by restriction enzyme digestion and sequencing. Lentivirus was generated using a third‐generation packaging system. Lenti‐OE MLL4 plasmid and two packaging plasmids (pLV2.1‐GAG‐POL and pLV2.1‐VSVG) were co‐transfected into LLC cells using Lipo6000 transfection reagent (Beyotime). Virus‐containing supernatants were collected at 48 and 72 h, filtered through a 0.45 μm membrane, and concentrated with Lenti‐X concentrator (TaKaRa, 631233). Viral titers were determined using the Lentivirus qPCR Quantification Kit (Abcam, AB289841). The cells were infected with lentivirus in the presence of 2 μg/mL polybrene overnight and selected with 2 μg/mL puromycin to establish stable cell lines. Statistical Analysis Data were analyzed using GraphPad Prism 9 and presented as mean ± SD. Comparisons among groups were performed using one‐way or two‐way ANOVA. p < 0.05 was considered statistically significant. Results HPLC Confirms the Chemical Consistency of FWHJ The major active components of FWHJ were identified and quantitatively analyzed by HPLC (Figure 1). Four characteristic peaks corresponding to chlorogenic acid, amygdalin, harpagoside, and naringin were observed. Quantitative analysis using the external standard method revealed that naringin (1.07 mg/g) was the predominant component, followed by chlorogenic acid (0.65 mg/g) and amygdalin (0.44 mg/g), while harpagoside (0.10 mg/g) was relatively low. The overall chromatographic profile exhibited well‐resolved peaks and high reproducibility, providing a reliable basis for quality control of FWHJ. HPLC analysis of the active components in FWHJ. (A) HPLC chromatograms of FWHJ samples; (B) HPLC chromatograms of reference standards. Peak numbers and corresponding contents are: (1) Chlorogenic acid (0.65 mg/g), (2) amygdalin (0.44 mg/g), (3) harpagoside (0.10 mg/g), and (4) naringin (1.07 mg/g). FWHJ Suppresses Tumor Growth in LLC‐Bearing Mice To evaluate the in vivo antitumor effect, FWHJ LLC‐bearing mice were orally administered low, medium, or high doses of FWHJ (1.17, 2.34, and 4.68 g/kg) once daily for 14 days. Body weight, tumor volume, and tumor weight were recorded throughout the experiment. Compared with the model group, FWHJ treatment significantly reduced tumor size and weight in a dose‐dependent manner (Figure 2A–C). In contrast, FWHJ treatment had no significant effect on body weight, suggesting no apparent toxicity (Figure 2D). FWHJ inhibited tumor growth in LLC‐bearing mice. (A) Representative photographs of tumors in each group. (B) Tumor volume changes in each group. (C) Tumor weight changes in each group. (D) Body weight changes of mice in each group; **p < 0.01 versus model group, mean ± SD, n = 12. (E) H&E staining of tumor tissues from each group. (F) TUNEL assay of tumor tissues from each group. (G) Quantification of TUNEL‐positive cells. **p < 0.01 versus model group, mean ± SD, n = 3. To further determine whether the tumor suppressive effect of FWHJ was associated with increased tumor cell death, H&E and TUNEL staining were performed. H&E staining revealed extensive necrotic regions in tumor tissues from the FWHJ‐treated group compared with the model group (Figure 2E). Consistently, the TUNEL assay showed a significant dose‐dependent increase in TUNEL‐positive cells, with the strongest effect observed in the high‐dose FWHJ group (Figure 2F,G). Together, these results indicate that FWHJ suppresses tumor growth in vivo, at least in part, by promoting tumor cell death without causing obvious systemic toxicity. We next sought to determine which form of programmed cell death was involved in this process. FWHJ Activates Caspase‐1/GSDMD‐Associated Pyroptosis‐Related Signaling Given that proptosis is a pro‐inflammatory form of programmed cell death that can promote antitumor immune responses, we examined the expression of pyroptosis‐related proteins in tumor tissues. Western blot analysis showed that NLRP3, cleaved caspase‐1, and GSDMD‐N levels were significantly increased in medium‐ and high‐dose FWHJ‐treated groups compared with the model group (Figure 3A–D). Consistently, immunohistochemistry revealed enhanced GSDMD staining in FWHJ‐treated tumor tissues (Figure 3E,F). In contrast, no significant change in cleaved caspase‐3 was observed following FWHJ treatment, suggesting that FWHJ‐induced cell death was not primarily associated with classical apoptosis (Figure 3G,H). ELISA assays further showed significant dose‐dependent increases in IL‐1β and IFN‐β levels in FWHJ‐treated groups (Figure 3I,J). To further assess whether caspase‐1 activity contributed to the antitumor effect, FWHJ LLC‐bearing mice were treated with high dose FWHJ (FWHJ‐H) in the presence or absence of the caspase‐1 inhibitor VX‐765. VX‐765 treatment partially attenuated the tumor‐suppressive effect of FWHJ, as indicated by increased tumor volume and tumor weight compared with FWHJ‐H treatment alone (Figure 3K–M). Together, these results suggest that FWHJ activates caspase‐1/GSDMD‐associated pyroptosis‐related signaling in tumor tissue, which may contribute to its antitumor effect. FWHJ activates pyroptosis in tumor tissues. (A) Western blot analysis of pyroptosis‐related proteins in different treatment groups. (B–D) Quantitative analysis of relative protein expression levels in different groups. (E and F) Immunohistochemical staining of GSDMD protein in tumor tissues of different groups. (G and H) Western blot analysis of classical apoptosis‐related proteins (cleaved caspase‐3) in different treatment groups. (I and J) ELISA analysis of IL‐1β and IFN‐β levels in tumor tissues; *p < 0.05, **p < 0.01 versus model group, mean ± SD, n = 3. (K–M) LLC‐bearing mice were treated with high‐dose FWHJ in the presence or absence of the caspase‐1 inhibitor VX‐765. Representative tumor images, tumor growth curve, and tumor weight are shown. *p < 0.05, **p < 0.01, mean ± SD, n = 6. FWHJ Enhances CD8 + T‐Cell‐Mediated Antitumor Immunity Since pyroptosis can promote inflammatory signaling and facilitate antitumor immune responses, we next examined whether FWHJ treatment enhanced T‐cell infiltration and activation in tumor tissues. Flow cytometry analysis was performed to analyze tumor‐infiltrating T‐cell subpopulations. Compared with the model group, FWHJ treatment significantly increased total CD3+ T‐cell infiltration (Figure 4A,B). Among tumor‐infiltrating T cells, FWHJ further increased the CD8+/CD4+ T cells ratio, as well as the frequencies of CD28+ CD8+ T cells and IFN‐γ+ CD8+ T cells (Figure 4C–H). These findings suggest that FWHJ enhances cytotoxic T‐cell infiltration and activation, thereby strengthening antitumor immunity. FWHJ enhanced immune cell infiltration in tumor tissues. (A and B) Flow cytometry analysis of CD3+ T‐cell infiltration in tumor tissues of different groups. (C and D) Flow cytometry analysis of CD4+ and CD8+ T cells in tumor tissues of different groups. (E and F) Flow cytometry analysis of CD28+ CD8+T cells in tumor tissues of different groups. (G and H) Flow cytometry analysis of IFN‐γ+ CD8+ T cells in tumor tissues of different groups; **p < 0.01 versus model group, mean ± SD, n = 3. (I and J) Flow cytometric validation of CD8+ T‐cell depletion in tumor tissues from LLC‐bearing mice treated with control IgG or anti‐CD8 antibody; (K–M) Representative tumor images, tumor growth curve, and tumor weight in LLC‐bearing mice treated with FWHJ‐H in combination with control IgG or anti‐CD8 antibody. *p < 0.05, **p < 0.01, mean ± SD, n = 6. To determine whether CD8+ T cells functionally contribute to the antitumor effect of FWHJ, we performed an in vivo CD8+ T‐cell depletion experiment. LLC‐bearing mice were treated with FWHJ‐H in combination with either control IgG or an anti‐CD8 antibody. Flow cytometric analysis confirmed efficient depletion of CD8+ T cells in tumor tissues following anti‐CD8 antibody treatment (Figure 4I,J). Importantly, CD8+ T‐cell depletion weakened the tumor‐suppressive effect of FWHJ, as indicated by increased tumor volume and tumor weight compared with the FWHJ‐H group (Figure 4K–M). These findings suggest that FWHJ enhances T‐cell infiltration and CD8+ T‐cell activation, and that CD8+ T cells contribute to FWHJ‐mediated tumor suppression. MLL4 Downregulation Is Associated With FWHJ‐Induced Pyroptosis and Antitumor Responses Given that FWHJ markedly activated pyroptosis‐related signaling and enhanced immune cell infiltration, we next sought to identify potential upstream regulators mediating these effects. Recent studies have reported that the histone methyltransferase MLL4 (KMT2D) not only modulates epigenetic transcriptional activity but also participates in the regulation of pyroptosis and antitumor immunity. Based on its functional relevance to the above observations, we therefore examined whether MLL4 expression was affected by FWHJ treatment. Western blot analysis revealed that MLL4 expression was significantly decreased in FWHJ‐treated groups compared with the model group (Figure 5A,B). Immunohistochemistry further confirmed these findings, showing strong MLL4 staining in the model group and gradual reduction with increasing FWHJ dosage (Figure 5C,D). To further determine whether FWHJ‐mediated MLL4 downregulation and pyroptosis‐related signaling could be observed in different lung cancer cell models, LLC, A549, and NCI‐H1975 cells were treated with FWHJ‐containing serum. Consistent with the in vivo findings, FWHJ‐containing serum decreased MLL4 expression and increased the levels of NLRP3, cleaved caspase‐1, and GSDMD‐N in these cell lines (Figure S1). These findings indicate that MLL4 downregulation may be associated with FWHJ‐induced pyroptosis. Overexpression of MLL4 attenuated the antitumor effects of FWHJ. (A and B) Western blot analysis showing MLL4 expression in different treatment groups. (C and D) Immunohistochemical staining showing MLL4 protein expression in tumor tissues of different groups. *p < 0.05, **p < 0.01 versus model group, mean ± SD, n = 3. (E) Western blot analysis confirming successful establishment of the MLL4 overexpression model. (F–H) Representative tumor photographs, tumor volume, and tumor weight in different groups, n = 12. (I and J) Flow cytometry analysis of CD4+ and CD8+ T cells in tumor tissues of different groups; **p < 0.01, mean ± SD, n = 3. (K) Western blot analysis of pyroptosis‐related proteins in different treatment groups. (L–N) Quantitative analysis of relative protein expression levels in different groups. (O and P) ELISA analysis of IL‐1β and IFN‐β levels in tumor tissues; *p < 0.05, **p < 0.01, mean ± SD, n = 3. To further validate whether MLL4 downregulation functionally contributes to the antitumor activity of FWHJ, an MLL4 overexpression model was established and subjected to high‐dose FWHJ treatment. Western blot analysis confirmed the successful induction of MLL4 expression (Figure 5E). Compared with the model group, high‐dose FWHJ significantly reduced tumor volume and weight. In contrast, tumors in MLL4‐overexpressing mice were larger and heavier. Notably, MLL4 overexpression weakened the tumor‐suppressive effect of FWHJ, as reflected by increased tumor volume and weight compared with the high‐dose FWHJ group alone (Figure 5F–H). Flow cytometry further revealed that MLL4 overexpression decreased the ratio of CD8+/CD4+ T cells and partially reversed FWHJ‐induced immune cell infiltration (Figure 5I,J). We further examined whether MLL4 overexpression affected the FWHJ‐induced pyroptosis‐related signaling. Compared with FWHJ‐H treatment alone, MLL4 overexpression reduced the expression of NLRP3, cleaved caspase‐1, and GSMD‐N in tumor tissues (Figure 5K–N). Consistently, ELISA assays showed that MLL4 overexpression decreased the FWHJ‐induced production of IL‐1β and IFN‐β (Figure 5O,P). These data suggest that FWHJ downregulates MLL4, whereas restoration of MLL4 expression attenuates FWHJ‐induced pyroptosis and antitumor immune responses. Discussion Lung cancer is one of the most common malignant tumors worldwide and remains a leading cause of cancer‐related mortality, posing a serious public health challenge [8]. Although the application of targeted therapies and immune checkpoint inhibitors has significantly improved cancer treatment in recent years, the majority of patients still experience limited efficacy due to immunosuppressive tumor microenvironments, immune evasion, and acquired resistance [9, 10]. Therefore, enhancing tumor immune infiltration and activating antitumor immune responses have become key objectives in lung cancer research. FWHJ, a traditional Chinese medicine formula targeting “Qi and Yin deficiency” in lung cancer patients, has been reported to exert antitumor, anti‐aging, and immunomodulatory effects [7]. In the present study, we combined chemical composition analysis, in vivo pharmacological evaluation, and mechanistic investigation to demonstrate that FWHJ not only significantly inhibited the growth of subcutaneous lung tumors in mice but also improved the antitumoral immune microenvironment via MLL4‐mediated pyroptosis, thereby exerting antitumor effects. HPLC analysis revealed that FWHJ primarily contains naringin, chlorogenic acid, amygdalin, and harpagoside, with naringin being the most abundant component. These compounds have been reported to possess anti‐inflammatory, antioxidant, and immunomodulatory properties, and they can inhibit tumor progression by regulating multiple signaling pathways [11, 12, 13, 14]. The synergistic effects of these active ingredients provide a chemical basis for the antitumor activity of FWHJ. In our LLC‐bearing mouse model, FWHJ significantly reduced tumor volume and weight without affecting body weight, suggesting antitumor efficacy with no apparent systemic toxicity. H&E and TUNEL staining further showed increased tumor cell death following FWHJ treatment, confirming its effect on tumor cells. Pyroptosis is a form of programmed cell death mediated by caspase‐1 activation, GSDMD cleavage, and release of pro‐inflammatory cytokines such as IL‐1β and IL‐18, as well as danger‐associated molecular patterns (DAMPs) like ATP and HMGB1, thereby activating local immune responses [15, 16]. In the tumor microenvironment, pyroptosis can convert immunologically “cold” tumors into more inflammatory and immune‐active lesions, thereby promoting antitumor immune responses [17, 18, 19, 20]. In this study, FWHJ significantly increased the expression of NLRP3, cleaved‐caspase‐1, and GSDMD‐N and enhanced GSDMD‐positive signals in tumor tissue, indicating activation of the pyroptosis pathway. Correspondingly, IL‐1β and IFN‐β levels were markedly elevated, further suggesting that FWHJ may promote tumor‐associated inflammatory responses via pyroptosis to stimulate antitumor immunity. In contrast, cleaved caspase‐3 was not significantly changed, suggesting that FWHJ‐induced tumor cell death was more closely associated with pyroptosis‐related signaling than with classical apoptosis. Furthermore, pharmacological inhibition of caspase‐1 with VX‐765 weakened the tumor‐suppressive effect of FWHJ, supporting the functional involvement of caspase‐1‐associated pyroptotic signaling in FWHJ‐mediated antitumor activity. Pyroptosis‐associated inflammatory signaling can further promote antitumor immunity by enhancing immune cell recruitment and activation. Consistent with this concept, FWHJ increased total CD3+ T‐cell infiltration in tumor tissues and enhanced the CD8+/CD4+ T‐cell ratio, as well as the frequencies of CD28+ CD8+ T cells and IFN‐γ+ CD8+ T cells. Importantly, in vivo depletion of CD8+ T cells weakened the tumor‐suppressive effect of FWHJ, indicating that CD8+ T cells functionally contribute to FWHJ‐mediated tumor control. These findings suggest that FWHJ not only induces tumor cell‐intrinsic pyroptosis‐related signaling but also promotes CD8+ T‐cell‐mediated antitumor immunity within the tumor microenvironment. MLL4, also known as KMT2D, is a histone methyltransferase involved in enhancer regulation and transcriptional activation. Previous studies have reported complex and context‐dependent roles of MLL4 in cancer [21]. In some tumor types, including certain lung cancer contexts, MLL4 loss or mutation has been associated with tumor progression, suggesting a tumor‐suppressive function [22]. However, MLL4 may also support tumor‐promoting transcriptional programs depending on cancer type, genetic background, disease stage, and the immune microenvironment. Notably, a recent study showed that MML4 ablation decommissions enhancers and elicits dsRNA‐interferon signaling and GSDMD‐mediated pyroptosis, thereby increasing tumor immunogenicity and potentiating antitumor T‐cell response [6, 23]. In line with this concept, our study found that FWHJ‐induced MLL4 downregulation was accompanied by increased IFN‐β production, Caspase‐1/GSDMD‐associated pyroptosis‐related signaling, and enhanced CD8+ T‐cell immune activation. Therefore, the biological consequence of MLL4 regulation should be interpreted in a context‐specific manner rather than as uniformly tumor‐suppressive or tumor‐promoting. In the present study, FWHJ significantly downregulated MLL4 expression in LLC tumor tissues. Additional in vitro validation using FWHJ‐containing serum further showed decreased MLL4 expression accompanied by increased pyroptosis‐related markers in multiple lung cancer cell lines, supporting the broader relevance of this response. More importantly, restoration of MLL4 expression attenuated the antitumor effect of FWHJ, reduced FWHJ‐induced NLRP3, cleaved caspase‐1, and GSDMD‐N expression, decreased IL‐1β and IFN‐β production, and weakened CD8+ T‐cell immune infiltration. These results indicate that MLL4 downregulation is closely linked to FWHJ‐induced pyroptosis‐related inflammatory signaling and antitumor immune responses. This study has several limitations. First, FWHJ is a complex multi‐component formula, and the specific constituent or combination of constituents responsible for MLL4 downregulation and pyroptosis activation remains to be identified. Future studies using fractionation‐guided screening and purified compounds will be needed to define the active components. Second, although additional lung cancer cell lines were used for in vitro validation, the main in vivo evidence was obtained from the LLC model. Validation in additional syngeneic, orthotopic, or humanized lung cancer models would further strengthen the translational relevance of the findings. Third, although VX‐765 and CD8+ T‐cell depletion experiments support the involvement of Caspase‐1 activity and CD8+ T cells, further studies using genetic approaches or cytokine pathway blockade will be useful to dissect the precise contribution of pyroptosis‐derived inflammatory mediators such as IL‐1β and type I interferon signaling. In summary, our study demonstrates that FWHJ suppresses lung tumor growth by activating an MLL4‐associated pyroptosis‐immunity axis. FWHJ downregulates MLL4, promotes caspase‐1/GSDMD‐associated pyroptosis‐related signaling, enhances inflammatory mediator production, and strengthens CD8+ T‐cell‐mediated antitumor immunity. These findings provide mechanistic insight into the antitumor activity of FWHJ and suggest that targeting the MLL4 may represent a potential therapeutic strategy for improving antitumor responses in lung cancer. A graphical summary of this proposed mechanism is shown in Figure 6. Feiwei Heji suppresses lung tumor growth by downregulating MLL4 and activating caspase‐1/GSDMD‐associated pyroptosis. This pyroptosis‐related inflammatory response enhances CD8+ T‐cell‐mediated antitumor immunity, revealing an MLL4‐pyroptosis‐immune axis underlying the therapeutic activity of Feiwei Heji. Author Contributions Nan Cheng: writing – review and editing, investigation, methodology. Ruoyu Jiang: investigation, writing – original draft. Wei Li: validation, formal analysis. Wenjie Huang: methodology, formal analysis. Qiao Peng: validation, investigation. Tong Zhao: writing – review and editing, conceptualization. Chufeng Zhang: conceptualization, writing – review and editing. Funding This work was supported by the Natural Science Foundation of Jiangsu Province (Grant no. BK20240753) and the Shandong Province Traditional Chinese Medicine Science & Technology Project (Grant no. M‐2022224). Ethics Statement All animal experiments were conducted in accordance with the Basel Declaration's tenets and the Laboratory Animal‐Guideline for Ethical Review of Animal Welfare (GB/T 35892‐2018) recommended by the Institutional Animal Care and Use Committee of Nanjing University of Chinese Medicine (animal ethics approval number 202401A041). Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: FWHJ‐containing serum downregulates MLL4 and activates pyroptosis‐related signaling in multiple lung cancer cell lines. Contributor Information Tong Zhao, Email: zhaotong@njucm.edu.cn. Chufeng Zhang, Email: zcf18866126280@163.com. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Figure S1: FWHJ‐containing serum downregulates MLL4 and activates pyroptosis‐related signaling in multiple lung cancer cell lines. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.